Brief report: Therapeutic benefit of ISA-2011B in colorectal cancer.

UNLABELLED: ISA-2011B is a phosphatidylinositol-4-phosphate 5-kinase-α (PIP5K1α) inhibitor that has been reported to be selective in suppressing the growth of prostate, breast and hepatic cancer cells. Here, cell viability of 2-dimensional (2D) cultures and 3-dimensional (3D) spheroids of four colorectal cancer (CRC) cell lines with different mutations were evaluated after treatment with the drug ISA-2011B. METHODS: The CRC cell lines were investigated for viability in 2D and 3D spheroid cultures. The 3D spheroids were subjected to imaging, and the average volumes were measured. RESULTS: The results show different treatment effects of ISA-2011B on the four CRC cell lines, indicating that mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) and phosphatidylinositol 3-kinase (PI3K) genes can play a role in the outcome of treatment. CONCLUSIONS: With additional studies, we suggest that ISA-2011B can be a promising drug target in CRC.